Azithromycin combination for emesis control in mammals
AssigneePfizer Inc.
InventorsDennis M. Godek, Richard Todd Darrington, Elizabeth Fraering Illyes
Life of this patent
Estimating the term…
Abstract
The invention is directed to a method of treating cancer or a bacterial or protozoal infection in a mammalian subject in need of such treatment. The method comprises the adjunctive administration of pharmaceutically effective amounts of a macrolide antibiotic and a Substance P antagonist. The invention also encompasses a method of preventing or treating emesis associated with macrolide antibiotic administration. The invention further encompasses novel compositions comprising a macrolide antibiotic and a Substance P antagonist.
Claims15
A method of treating cancer or a bacterial or protozoal infection comprising the adjunctive administration to a mammalian subject in need of such treatment of a pharmaceutically effective amount of a macrolide antibiotic and a pharmaceutically effective amount of a Substance P antagonist.
A method of preventing or treating emesis associated with a macrolide antibiotic comprising administering to a subject in need of such prevention or treatment a pharmaceutically effective amount of a Substance P antagonist.
11) A pharmaceutical composition comprising a pharmaceutically effective amount of a macrolide antibiotic, a pharmaceutically effective amount of a Substance P antagonist, and optionally, a carrier.
15) A method of treating cancer comprising the adjunctive administration to a mammalian subject in need of such treatment of a pharmaceutically effective amount of a macrolide antibiotic and a pharmaceutically effective amount of a Substance P antagonist.
Dependencies are inferred from the claim text.